Table 1.
Pooled analysis.
| Total patients | 373 children |
| Sex | 254F (68.1%) 119 M (31.9%) |
| Mean age | 9.98 years (range, 3–18 years) |
| Teratoma or malignancy present | 66 (17.6%) |
| CSF positive for anti-NMDAR | 327 (87.6%) |
| Serum positive for anti-NMDAR | 276 (74%) |
| First-line treatments | |
| High-dose corticosteroids | 335 (89.8%) |
| Intravenous immunoglobulin | 296 (79.3%) |
| Plasma exchange | 116 (31%) |
| Second-line treatments | |
| Rituximab | 87 (23.3%) |
| Cyclophosphamide | 62 (16.6%) |
| Third-line treatments | |
| Electroconvulsive therapy | 5 (1.3%) |
| Mechanical ventilation | 14 (3.8%) |
| Outcomes | |
| Complete recovery with minor deficits | 187 (50.1%) |
| Partial recovery with major deficits | 174 (46.7%) |
| Death | 12 (3.2%) |